MarketScreener Editorial Features Atossa Genetics Inc Nasdaq
Equities
US04962H1005
End-of-day quote
Other stock markets
|
||
- USD | - |
15/05 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
15/05 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
- Stock Market
- Equities
- ATOS Stock
- Stock
- News Atossa Genetics Inc
- MarketScreener Editorial Features